Meta-analyses of randomized trials have shown that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce the risk of incident AF, though the benefits are less consistent in individuals without structural heart disease [184]. This evidence concerns the gene ACE and atrial fibrillation.